Cannabidiol arrests onset of autoimmune diabetes in NOD mice

Neuropharmacology

Volumn 54, Issue 1, 2008, Pages 244-249

  Weiss, Lola ^a   Zeira, Michael ^a   Reich, Shoshana ^a   Slavin, Shimon ^a   Raz, Itamar ^b   Mechoulam, Raphael ^c   Gallily, Ruth ^b  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b HEBREW UNIVERSITY   (Israel)

^c HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

Cannabidiol; Cannabinoids; Cytokines; Diabetes; NOD mice

Indexed keywords

CANNABIDIOL; INTERLEUKIN 10; INTERLEUKIN 12;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL INFILTRATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DIABETES MELLITUS; DRUG MECHANISM; FEMALE; HISTOPATHOLOGY; MOUSE; NONHUMAN; NONOBESE DIABETIC MOUSE; PRIORITY JOURNAL; SPLEEN CELL;

ANIMALS; CANNABIDIOL; CYTOKINES; DIABETES MELLITUS, TYPE 1; DISEASE MODELS, ANIMAL; FEMALE; GENE EXPRESSION REGULATION; LYMPHOCYTES; MACROPHAGES; MICE; MICE, INBRED NOD; STATISTICS, NONPARAMETRIC;

EID: 37349096614     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2007.06.029     Document Type: Article

References (39)

1. Anderson M.S., and Bluestone J.A. The NOD mouse: a model of immune dysregulation. Annu. Rev. Immunol. 23 (2005) 447-485
2. Atkinson M.A., and Leiter E.H. The NOD mouse model of type 1 diabetes: as good as it gets?. Nat. Med. 5 (1999) 601-604
3. Awad A.S., Huang L., Ye H., Duong E.T., Bolton W.K., Linden J., and Okusa M.D. Adenosine A2A receptor activation attenuates inflammation and injury in diabetic nephropathy. Am. J. Physiol. Renal Physiol. 290 (2006) F828-F837
4. Baeder W.L., Sredy J., Sehgal S.N., Chang J.Y., and Adams L.M. Rapamycin prevents the onset of insulin-dependent diabetes mellitus (IDDM) in NOD mice. Clin. Exp. Immunol. 89 (1992) 174-178
5. Ben-Shabat S., Hanus L.O., Katzavian G., and Gallily R. New cannabidiol derivatives: synthesis, binding to cannabinoid receptors and evaluation of their antiinflammatory activity. J. Med. Chem. 49 (2006) 1113-1117
6. Bermudez-Siva F.J., Serrano A., Diaz-Molina F.J., Sanchez Vera I., Juan-Pico P., Nadal A., Fuentes E., and Rodriguez de Fonseca F. Activation of cannabinoid CB1 receptors induces glucose intolerance in rats. Eur. J. Pharmacol. 531 (2006) 282-284
7. Cameron M.J., Arreaza G.A., Zucker P., Chensue S.W., Strieter R.M., Chakrabarti S., and Delovitch T.L. IL-4 prevents insulitis and insulin-dependent diabetes mellitus in nonobese diabetic mice by potentiation of regulatory T helper-2 cell function. J. Immunol. 159 (1997) 4686-4692
8. Carrier E.J., Auchampach J.A., and Hillard C.J. Inhibition of an equilibrative nucleoside transporter by cannabidiol: a mechanism of cannabinoid immunosuppression. Proc. Natl. Acad. Sci. U.S.A. 103 (2006) 7895-7900
9. Chan S.H., Perussia B., Gupta J.W., Kobayashi M., Pospisil M., Young H.A., Wolf S.F., Young D., Clark S.C., and Trinchieri G. Induction of interferon gamma production by natural killer cell stimulatory factor: characterization of the responder cells and synergy with other inducers. J. Exp. Med. 173 (1991) 869-879
10. Corbett J.A., Lancaster J.R., and Sweetland M.A. Interleukin-1 beta-induced formation of EPR-detectable iron-nitrosyl complexes in islets of Langerhans. Role of nitric oxide in interleukin-1 beta-induced inhibition of insulin secretion. J. Biol. Chem. 266 (1991) 21351-21354
11. Crane I.J., and Forrester J.V. Th1 and Th2 lymphocytes in autoimmune disease. Crit. Rev. Immunol. 25 (2005) 75-102
12. Cunha J.M., Carlini E.A., Pereira A.E., Ramos O.L., Pimentel C., Gagliardi R., Sanvito W.L., Lander N., and Mechoulam R. Chronic administration of cannabidiol to healthy volunteers and epileptic patients. Pharmacology 21 (1980) 175-185
13. Elenkov I.J., Iezzoni D.G., Daly A., Harris A.G., and Chrousos G.P. Cytokine dysregulation, inflammation and well-being. Neuroimmunomodulation 12 (2005) 255-269
14. 1-THC and other neutral cannabinoids from hashish. J. Am. Chem. Soc. 93 (1971) 217-224
15. Gelfand E.V., and Cannon C.P. Rimonabant: a cannabinoid receptor type 1 blocker for management of multiple cardiometabolic risk factors. J. Am. Coll. Cardiol. 47 (2006) 1919-1926
16. Grden M., Podgorska M., Szutowicz A., and Pawelczyk T. Altered expression of adenosine receptors in heart of diabetic rat. J. Physiol. Pharmacol. 56 (2005) 587-597
17. Gross D.J., Weiss L., Reibstein I., Van den Brand J., Okamoto H., and Clark A. Amelioration of diabetes in nonobese diabetic mice with advanced disease by linomide-induced immunoregulation combined with Reg protein treatment. Endocrinology 139 5 (1998) 2369-2374
18. Ji Y.H., Weiss L., Zeira M., Abdul-Hai A., Har-Noy M., and Slavin S. Allogeneic cell-mediated immunotherapy of leukemia with immune donor lymphocytes to upregulate antitumor effects and downregulate antihost responses. Bone Marrow Transplant. 32 (2003) 495-504
19. 2+ signals and insulin secretion in pancreatic β-cells. Cell Calcium 39 (2006) 155-162
20. Kai N., Motojima K., Tsunoda T., and Kanematsu T. Prevention of insulitis and diabetes in nonobese diabetic mice by administration of FK506. Transplantation 55 (1993) 936-940
21. Keymeulen B., Vandemeulebroucke E., Ziegler A.G., Mathieu C., Kaufman L., Hale G., Gorus F., Goldman M., Walter M., Candon S., Schandene L., Crenier L., De Block C., Seigneurin J.M., De Pauw P., Pierard D., Weets I., Rebello P., Bird P., Berrie E., Frewin M., Waldmann H., Bach J.F., Pipeleers D., and Chatenoud L. Insulin needs after CD3 antibody therapy in new-onset type 1 diabetes. N. Engl. J. Med. 352 (2005) 2598-2608
22. Malfait A.M., Gallily R., Sumariwalla P.F., Malik A.S., Andreakos E., Mechoulam R., and Feldmann M. The non-psychoactive cannabis-constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis. Proc. Natl. Acad. Sci. U.S.A. 97 (2000) 9561-9566
23. Mandrup-Poulsen T. Beta cell death and protection. Ann. NY Acad. Sci. 1005 (2003) 32-42
24. Meierhoff G., Ott P.A., Lehmann P.V., and Schloot N.C. Cytokine detection by ELISPOT: relevance for immunological studies in type 1 diabetes. Diabetes Metab. Res. Rev. 18 (2002) 367-380
25. Mueller R., Krahl T., and Sarvetnick N. Pancreatic expression of interleukin-4 abrogates insulitis and autoimmune diabetes in nonobese diabetic (NOD) mice. J. Exp. Med. 184 (1996) 1093-1099
26. Rabinovitch A. Immunoregulation by cytokines in autoimmune diabetes. Adv. Exp. Med. Biol. 520 (2003) 159-193
27. Rabinovitch A., Suarez-Pinzon W.L., Sorensen O., Bleackley R.C., Power R.F., and Rajotte R.V. Combined therapy with interleukin-4 and interleukin-10 inhibits autoimmune diabetes recurrence in syngeneic islet-transplanted nonobese diabetic mice. Analysis of cytokine mRNA expression in the graft. Transplantation 60 (1995) 368-374
28. Rabinovitch A., Suarez-Pinzon W.L., and Sorensen O. Interleukin 12 mRNA expression in islets correlates with beta-cell destruction in NOD mice. J. Autoimmun. 9 (1996) 645-651
29. Rapoport M.J., Jaramillo A., Zipris D., Lazarus A.H., Serreze D.V., Leiter E.H., Cyopick P., Danska J.S., and Delovitch T.L. Interleukin 4 reverses T-cell proliferative unresponsiveness and prevents the onset of diabetes in nonobese diabetic mice. J. Exp. Med. 178 (1993) 87-99
30. Raz I., Elias D., Avron A., Tamir M., Metzger M., and Cohen I.R. Beta-cell function in new-onset type 1 diabetes and immunomodulation with a heat-shock protein peptide (DiaPep277): a randomised, double-blind, phase II trial. Lancet 358 (2001) 1749-1753
31. Rothe H., Burkart V., Faust A., and Kolb H. Interleukin-12 gene expression is associated with rapid development of diabetes mellitus in non-obese diabetic mice. Diabetologia 39 (1996) 119-122
32. Shi Q., Wang D., Hadley G.A., Farber D.L., and Bartlett S.T. Abrogation of recurrent autoimmunity in the NOD mouse: a critical role for host interleukin 4. Surgery 140 (2006) 281-288
33. Thomas A., Baillie G.L., Phillips A.M., Razdan R.K., Ross R.A., and Pertwee R.G. Cannabidiol displays unexpectedly high potency as an antagonist of CB(1) and CB(2) receptor agonists in vitro. Br. J. Pharmacol. 150 (2007) 613-623
34. Thong F.S., and Graham T.E. The putative roles of adenosine in insulin- and exercise-mediated regulation of glucose transport and glycogen metabolism in skeletal muscle. Can. J. Appl. Physiol. 27 (2002) 152-178
35. Tominaga Y., Nagata M., Yasuda H., Okamoto N., Arisawa K., Moriyama H., Miki M., Yokono K., and Kasuga M. Administration of IL-4 prevents autoimmune diabetes but enhances pancreatic insulitis in NOD mice. Clin. Immunol. Immunopathol. 86 (1998) 209-218
36. Trembleau S., Penna G., Bosi E., Mortara A., Gately M.K., and Adorini L. Interleukin 12 administration induces T helper type 1 cells and accelerates autoimmune diabetes in NOD mice. J. Exp. Med. 81 (1995) 817-821
37. Trinchieri G. Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity. Annu. Rev. Immunol. 13 (1995) 251-276
38. Verma N.D., Boyd R., Robinson C., Plain K.M., Tran G.T., and Hall B.M. Interleukin-12p70 prolongs allograft survival by induction of interferon gamma and nitric oxide production. Transplantation 82 (2006) 1324-1333
39. Weiss L., Zeira M., Reich S., Har-Noy M., Mechoulam R., Slavin S., and Gallily R. Cannabidiol lowers incidence of diabetes in non-obese diabetic mice. Autoimmunity 39 (2006) 143-151